POWER OF KNOWLEDGE

Insight Center: News

Pepper Hamilton Advises Interpace Diagnostics in Acquisition of Biopharma Business of Cancer Genetics

8/05/2019
Pepper Hamilton Advises Interpace Diagnostics in Acquisition of Biopharma Business of Cancer Genetics

Pepper Hamilton served as legal advisor to Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) in its acquisition of assets and certain liabilities constituting the biopharma services business of Cancer Genetics, Inc. (NASDAQ: CGIX).

The $23.5 million  acquisition accomplished through an Article 9 foreclosure sale by secured creditors of Cancer Genetics is expected to create a leading oncology testing and service company in the clinical diagnostic and biopharma markets, leveraging sophisticated assays, novel algorithms and custom service capabilities across the continuum of oncology, from precancerous assessment to drug discovery and clinical trial support.

Pepper Hamilton also represented Interpace in a concurrent  investment by an affiliate of  Ampersand Capital Partners, one of the leading private equity firms in the diagnostic/biopharma sector. In conjunction with Interpace’s biopharma business acquisition, Ampersand  agreed to invest $27 million in Interpace in two tranches of newly issued convertible preferred stock, a portion of which will be subject to approval by Interpace’s shareholders.

The Pepper team was led by Merrill M. Kraines. Other team members included partners Nilufer R. Shaikh, David M. Fournier and Judith L. O’Grady; of counsel Todd R. Kornfeld and Rebecca Alperin; and associates Cagatay Akkoyun, M. Corey Connelly, Kirk Dungca, Victoria Laubach, Jennifer Lang, and Noreen Hibbard Onimus.

View News

Data protection laws have changed, so we have revised our Privacy Policy.

CLOSE